Leerink Partnrs Predicts Stronger Earnings for XOMA Royalty

Key Points

• Leerink Partners has raised their FY2026 earnings per share (EPS) estimate for XOMA Royalty to $0.67, increasing from a prior estimate of $0.61, despite a current consensus estimate of (1.41) EPS.
• XOMA Royalty's stock has shown resilience, with recent trading reaching $31.87, and it has seen a significant market capitalization of $381.47 million.
• Insider activity includes CEO Owen Hughes selling 25,637 shares, reducing his ownership by 29.02% to approximately $1.59 million in stock value.

XOMA Royalty Corporation (NASDAQ:XOMA - Free Report) - Investment analysts at Leerink Partnrs boosted their FY2026 earnings per share (EPS) estimates for shares of XOMA Royalty in a research note issued on Thursday, August 14th. Leerink Partnrs analyst D. Risinger now anticipates that the biotechnology company will post earnings of $0.67 per share for the year, up from their previous estimate of $0.61. The consensus estimate for XOMA Royalty's current full-year earnings is ($1.41) per share.

XOMA Royalty (NASDAQ:XOMA - Get Free Report) last posted its earnings results on Wednesday, August 13th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.60. The company had revenue of $13.13 million during the quarter, compared to analyst estimates of $9.39 million. XOMA Royalty had a positive return on equity of 2.63% and a negative net margin of 27.57%.

Several other equities analysts have also issued reports on the company. Wall Street Zen upgraded XOMA Royalty from a "hold" rating to a "buy" rating in a research report on Monday, August 11th. Zacks Research raised XOMA Royalty to a "hold" rating in a research report on Tuesday, August 12th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $104.00 price target on shares of XOMA Royalty in a research report on Wednesday, May 28th. Two analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $69.50.

XOMA Royalty Stock Up 1.2%

Shares of XOMA traded up $0.40 on Friday, hitting $32.46. The company's stock had a trading volume of 64,129 shares, compared to its average volume of 44,093. The company has a quick ratio of 4.88, a current ratio of 4.88 and a debt-to-equity ratio of 1.41. The firm's fifty day moving average price is $26.68 and its 200-day moving average price is $24.41. XOMA Royalty has a fifty-two week low of $18.35 and a fifty-two week high of $35.00. The firm has a market capitalization of $392.38 million, a price-to-earnings ratio of -20.94 and a beta of 1.00.

Institutional Investors Weigh In On XOMA Royalty

Several large investors have recently made changes to their positions in the stock. Nuveen Asset Management LLC boosted its holdings in shares of XOMA Royalty by 3.8% in the 4th quarter. Nuveen Asset Management LLC now owns 14,363 shares of the biotechnology company's stock valued at $377,000 after buying an additional 527 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of XOMA Royalty by 13.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company's stock valued at $112,000 after buying an additional 543 shares during the last quarter. Eversept Partners LP boosted its holdings in shares of XOMA Royalty by 1.2% in the 4th quarter. Eversept Partners LP now owns 95,417 shares of the biotechnology company's stock valued at $2,508,000 after buying an additional 1,128 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in shares of XOMA Royalty by 38.0% in the 4th quarter. Wells Fargo & Company MN now owns 4,300 shares of the biotechnology company's stock valued at $113,000 after buying an additional 1,183 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in shares of XOMA Royalty by 1.5% in the 4th quarter. Northern Trust Corp now owns 91,181 shares of the biotechnology company's stock valued at $2,396,000 after buying an additional 1,340 shares during the last quarter. Institutional investors and hedge funds own 95.92% of the company's stock.

XOMA Royalty Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.